A novel series of N-aryltriazole and N-acridinyltriazole hybrids as potential anticancer agents

Keyphrases

• 1,3-dipolar Cycloaddition 100%
• 1H-1,2,3-triazole 100%
• Triazole 100%
• Novel Anticancer Agents 100%
• Anticancer Agents 66%
• Trisubstituted 66%
• Cervical Cancer 33%
• Leukemia 33%
• Cancer Cell Lines 33%
• HeLa 33%
• Kidney Cancer 33%
• Cytotoxic Activity 33%
• Sodium Azide 33%
• Regioisomers 33%
• Tunability 33%
• Lung Cancer A549 Cells 33%
• Copper-catalyzed 33%
• Micromolar Concentration 33%
• Premier 33%
• 1,2,3-triazole 33%
• 2D NMR Spectroscopy 33%
• Biological Significance 33%
• 1D NMR 33%
• Benzyl 33%
• Pharmacophore 33%
• Triazole Derivatives 33%
• Internal Alkynes 33%
• Structural Elaboration 33%
• Nucleophilic Substitution 33%
• Anticancer Evaluation 33%
• Azaheterocycles 33%
• Silyl Group 33%
• Terminal Alkynes 33%
• Acridine 33%
• Azide-alkyne 33%
• Cancer Burden 33%
• Molecular Hybrids 33%
• Aryl Chlorides 33%
• Liquid Chromatography-high Resolution Mass Spectrometry (LC-HRMS) 33%
• Human Embryonic Kidney 293 (HEK293) 33%
• Copper-catalyzed Azide-alkyne Cycloaddition (CuAAC) 33%
• Thermally Controlled 33%
• Silylated 33%
• High Regioselectivity 33%
• N-aryl 33%
• Potential Leads 33%
• Organic Azides 33%
• Synthetic Precursors 33%
• Triazoles Moiety 33%

Chemistry

• Antineoplastic Agent 100%
• Triazole 100%
• 1,3-cycloaddition 60%
• 1H-1,2,3-triazole 60%
• Alkyne 60%
• Azide 40%
• High Resolution Mass Spectrometry (HRMS) 20%
• Click Chemistry 20%
• 1,2,3-triazole 20%
• Two-Dimensional NMR 20%
• Regioselectivity 20%
• Acridine 20%
• 1D NMR Spectroscopy 20%
• Silyl Group 20%
• Heterocyclic Compound 20%
• Sodium Azide 20%
• Nucleophilic Substitution 20%
• Chloride 20%